These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 2366310)

  • 1. Analysis of ventricular arrhythmias in patients with dilated cardiomyopathy--relationship between the effects of antiarrhythmic agents and severity of myocardial lesions.
    Takarada A; Yokota Y; Fukuzaki H
    Jpn Circ J; 1990 Mar; 54(3):260-71. PubMed ID: 2366310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drugs and the heart. IV. Antiarrhythmic agents.
    Opie LH
    Lancet; 1980 Apr; 1(8173):861-8. PubMed ID: 6103220
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical pharmacology of antiarrhythmic drugs: a review and overview, part II.
    Singh BN; Cho YW; Kuemmerle HP
    Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):185-99. PubMed ID: 6788721
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of antiarrhythmic drugs in prevention of sudden cardiac death.
    Podrid PJ
    Cardiovasc Clin; 1985; 15(3):265-86. PubMed ID: 2421903
    [No Abstract]   [Full Text] [Related]  

  • 5. Beneficial antiarrhythmic effect of beta-blockade in patients with dilated cardiomyopathy.
    Kihara K; Koga Y; Wada T; Toshima H
    Jpn Circ J; 1992 Jan; 56(1):77-85. PubMed ID: 1371571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New drugs for treatment of ventricular arrhythmias.
    Heger JJ; Prystowsky EN; Zipes DP
    Heart Lung; 1981; 10(3):475-83. PubMed ID: 6785255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of disopyramide and mexiletine used alone and in combination for ventricular arrhythmias in patients with and without overt heart disease.
    Tanabe T; Takahashi K; Yoshioka K; Goto Y
    Int J Cardiol; 1991 Sep; 32(3):303-12. PubMed ID: 1724233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiarrhythmic drugs: clinical pharmacology and therapeutic uses.
    Anderson JL; Harrison DC; Meffin PJ; Winkle RA
    Drugs; 1978 Apr; 15(4):271-309. PubMed ID: 648399
    [No Abstract]   [Full Text] [Related]  

  • 9. Quantitative analysis of the antiarrhythmic effect of drugs on canine ventricular arrhythmias by the determination of minimum effective plasma concentrations.
    Hashimoto K; Shibuya T; Satoh H; Imai S
    Jpn Circ J; 1983 Jan; 47(1):92-7. PubMed ID: 6827775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New antiarrhythmic agents: amiodarone, aprindine, disopyramide, ethmozin, mexiletine, tocainide, verapamil.
    Zipes DP; Troup PJ
    Am J Cardiol; 1978 May; 41(6):1005-24. PubMed ID: 352121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of NS-2, a new class 1 antiarrhythmic agent, and AFD-19, its active metabolite, on ventricular arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized rats: comparison with disopyramide and mexiletine.
    Komori S; Sawanobori T; Tamura K; Kane KA; Parratt JR
    Jpn J Pharmacol; 1994 Jul; 65(3):193-200. PubMed ID: 7799519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac arrhythmias in the elderly: antiarrhythmic drug treatment.
    Nestico PF; Morganroth J
    Cardiol Clin; 1986 May; 4(2):285-303. PubMed ID: 3085932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of sudden coronary death by chronic antiarrhythmic therapy.
    Koch-Weser J
    Adv Cardiol; 1978; 25():206-28. PubMed ID: 360790
    [No Abstract]   [Full Text] [Related]  

  • 14. Late ventricular potentials and spontaneous and induced ventricular arrhythmias in dilated or hypertrophic cardiomyopathies. A prospective study about 83 patients.
    Fauchier JP; Cosnay P; Moquet B; Balleh H; Rouesnel P
    Pacing Clin Electrophysiol; 1988 Nov; 11(11 Pt 2):1974-83. PubMed ID: 2463575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of disopyramide and aprindine on arrhythmias after acute myocardial infarction.
    Pouleur H; Chaudron JM; Reyns P
    Eur J Cardiol; 1977 Jul; 5(5):397-404. PubMed ID: 330168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Long-term drug therapy in ventricular cardiac arrhythmias. Is an improvement of the prognosis possible?].
    Lüderitz B; Manz M; Steinbeck G
    Dtsch Med Wochenschr; 1983 Nov; 108(44):1663-7. PubMed ID: 6414795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy of mexiletine alone and in combination with class Ia antiarrhythmic drugs for refractory ventricular arrhythmias.
    Whitford EG; McGovern B; Schoenfeld MH; Garan H; Newell JB; McElroy M; Ruskin JN
    Am Heart J; 1988 Feb; 115(2):360-6. PubMed ID: 3341170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of antiarrhythmic drugs.
    Harrison DC; Meffin PJ; Winkle RA
    Prog Cardiovasc Dis; 1977; 20(3):217-42. PubMed ID: 335439
    [No Abstract]   [Full Text] [Related]  

  • 19. Relation of complex ventricular arrhythmias to presenting features and prognosis in dilated cardiomyopathy.
    Pelliccia F; Gallo P; Cianfrocca C; d'Amati G; Bernucci P; Reale A
    Int J Cardiol; 1990 Oct; 29(1):47-54. PubMed ID: 2262215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiarrhythmic effects of combined application of class I antiarrhythmic drugs; addition of low-dose mexiletine-enhanced antiarrhythmic effects of disopyramide and aprindine in various-rate canine ventricular tachycardias.
    Awaji T; Hashimoto K
    J Cardiovasc Pharmacol; 1993 Jun; 21(6):960-6. PubMed ID: 7687723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.